Table 3.
Genotypes of the BACH1 Ser919Pro variant among 866 unselected breast cancer patients and 731 healthy population controls.
| Cases | Controls | ||||||
| n | % | n | % | OR* | 95% CI | p | |
| Unselected breast cancer patients, all | 866 | 731 | |||||
| Pro/Pro | 184 | 21.2 | 148 | 20.2 | 1 | ||
| Pro/Ser | 428 | 49.4 | 382 | 52.3 | 0.901 | 0.697–1.165 | 0.427 |
| Ser/Ser | 254 | 29.3 | 201 | 27.5 | 1.016 | 0.765–1.351 | 0.911 |
| Pro/Ser + Ser/Ser | 682 | 78.8 | 583 | 79.8 | 0.941 | 0.738–1.120 | 0.623 |
| Unselected breast cancer patients, diagnosis <50 years | 276 | 476 | |||||
| Pro/Pro | 56 | 20.3 | 96 | 20.2 | 1 | ||
| Pro/Ser | 140 | 50.7 | 249 | 52.3 | 0.964 | 0.653–1.423 | 0.853 |
| Ser/Ser | 80 | 29 | 131 | 27.5 | 1.047 | 0.680–1.611 | 0.835 |
| Pro/Ser + Ser/Ser | 220 | 79.7 | 380 | 79.8 | 0.993 | 0.686–1.436 | 0.968 |
| Unselected breast cancer patients, diagnosis ≥50 years | 590 | 255 | |||||
| Pro/Pro | 128 | 21.7 | 52 | 20.4 | 1 | ||
| Pro/Ser | 288 | 48.8 | 133 | 52.2 | 0.878 | 0.600–1.289 | 0.511 |
| Ser/Ser | 174 | 29.5 | 70 | 27.5 | 1.010 | 0.660–1.545 | 0.964 |
| Pro/Ser + Ser/Ser | 462 | 78.3 | 203 | 79.6 | 0.925 | 0.644–1.328 | 0.671 |
* as compared to Pro/Pro homozygotes